The Department of Health has finally come to its senses by demanding for a full reimbursement of P3.5-billion-worth of Dengvaxia vaccines from Sanofi Pasteur, bought under the DOH’s massive immunization program.
I fully blame Sanofi for withholding its advisory during the contract signing that the vaccine, when given to subjects who have not been previously infected by the dengue virus, can develop a more serious form of the disease called dengue hemorrhagic fever with overall bleeding tendencies to vital organs like the brain, liver, lungs, gastrointestinal tract and skin. With uncontrolled bleeding, the patient goes into hemorrhagic shock or syndrome and ultimately, dies. Corticosteroids had been tried but were not successful.
ELISEO R. REBLANDO, MD past president, Private Hospitals Association of the Philippines